Healthy Clinical Trial
— ATMOfficial title:
Harnessing Macrophage Lysosomal Lipid Metabolism in Obesity-Associated Diseases
The goal of this study is to evaluate the role of transcription factor EB (TFEB) in adipose (fat) tissue macrophages (ATM) in regulating adipose tissue and systemic metabolic function in obesity. The investigators will assess the differences in ATM lipid metabolism in people with metabolically abnormal obesity and lean individuals. Both groups will have: - screening visit - imaging (body composition testing - dual-energy x-ray absorptiometry (DEXA) scans, magnetic resonance imaging [MRI] and magnetic resonance spectroscopy [MRS] scans) - Overnight visit with intravenous infusion (IV), muscle, and fat tissue biopsies Participants with obesity will complete meetings with study team members for a weight loss intervention to achieve a 10% body weight loss.
Status | Not yet recruiting |
Enrollment | 60 |
Est. completion date | March 2028 |
Est. primary completion date | March 2028 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 18 Years to 70 Years |
Eligibility | Inclusion Criteria : - age: =18 but =70 years - not pregnant or breastfeeding - weight stable and sedentary before enrollment - no use tobacco products, excessive amounts of alcohol, or dietary supplements, or medications known to or suspected to affect glucose and lipid metabolism (aside from certain medications used to treat diabetes in the metabolically abnormal obesity [MAO]-Type 2 Diabetes group) - no evidence of significant organ system dysfunction or disease (e.g. chronic severe kidney disease, cancer) - participants must fulfil all of the following group-specific inclusion criteria below: Lean group: - Body mass index (BMI) =18.5 but <25.0 kg/m2 - Intrahepatic triglyceride (IHTG) content <5% - fasting blood glucose concentration: <100 mg/dl - blood glucose concentration 2 h after a 75 g oral glucose challenge: <140 mg/dl - Hemoglobin A1C (HbA1c) <5.7 % Metabolically normal obesity (MNO) group: - BMI =30.0 but <45.0 kg/m2 - IHTG content <5% - fasting blood glucose concentration: <100 mg/dl - blood glucose concentration 2 h after a 75 g oral glucose challenge: <140 mg/dl - HbA1c <5.7 % Metabolically abnormal obesity (MAO)-insulin resistance and non-alcoholic fatty liver disease (NAFLD) group: - BMI =30.0 but <45.0 kg/m2 - IHTG content >7.5% - fasting blood glucose concentration: =100 but <126 mg/dl - blood glucose concentration 2 h after a 75 g oral glucose challenge: =140 but <200 mg/dl - HbA1c: =5.7 but <6.4 % MAO-type 2 diabetes group: - BMI =30.0 but <45.0 kg/m2 - clinical diagnosis of type 2 diabetes or fasting blood glucose concentration >126 mg/dl or blood glucose concentration 2 h after a 75 g oral glucose challenge>200 mg/dl or HbA1c >6.4 % without medication if not diagnosed and medically treated for diabetes Exclusion Criteria: - Individuals that do not meet all inclusion Criterion |
Country | Name | City | State |
---|---|---|---|
United States | University of Missouri School of Medicine | Columbia | Missouri |
Lead Sponsor | Collaborator |
---|---|
Bettina Mittendorfer | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), National Institutes of Health (NIH) |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Insulin sensitivity assessed as insulin-mediated glucose disposal during a hyperinsulinemic-euglycemic clamp procedure. | up to 6 months after the intervention | ||
Primary | 24-hour plasma glucose concentration | up to 6 months after the intervention | ||
Primary | Macrophage isolation in adipose tissue biopsy | macrophage gene expression using RNA sequencing and fluorescent activated cell sorting (FACS) | up to 6 months after the intervention | |
Primary | Macrophage isolation in skeletal muscle tissue | macrophage gene expression using RNA sequencing and fluorescent activated cell sorting (FACS) | up to 6 months after the intervention |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT06052553 -
A Study of TopSpin360 Training Device
|
N/A | |
Completed |
NCT05511077 -
Biomarkers of Oat Product Intake: The BiOAT Marker Study
|
N/A | |
Recruiting |
NCT04632485 -
Early Detection of Vascular Dysfunction Using Biomarkers From Lagrangian Carotid Strain Imaging
|
||
Completed |
NCT05931237 -
Cranberry Flavan-3-ols Consumption and Gut Microbiota in Healthy Adults
|
N/A | |
Terminated |
NCT04556032 -
Effects of Ergothioneine on Cognition, Mood, and Sleep in Healthy Adult Men and Women
|
N/A | |
Completed |
NCT04527718 -
Study of the Safety, Tolerability and Pharmacokinetics of 611 in Adult Healthy Volunteers
|
Phase 1 | |
Completed |
NCT04065295 -
A Study to Test How Well Healthy Men Tolerate Different Doses of BI 1356225
|
Phase 1 | |
Completed |
NCT04998695 -
Health Effects of Consuming Olive Pomace Oil
|
N/A | |
Completed |
NCT04107441 -
AX-8 Drug Safety, Tolerability and Plasma Levels in Healthy Subjects
|
Phase 1 | |
Completed |
NCT01442831 -
Evaluate the Absorption, Metabolism, And Excretion Of Orally Administered [14C] TR 701 In Healthy Adult Male Subjects
|
Phase 1 | |
Terminated |
NCT05934942 -
A Study in Healthy Women to Test Whether BI 1358894 Influences the Amount of a Contraceptive in the Blood
|
Phase 1 | |
Recruiting |
NCT05525845 -
Studying the Hedonic and Homeostatic Regulation of Food Intake Using Functional MRI
|
N/A | |
Completed |
NCT05515328 -
A Study in Healthy Men to Test How BI 685509 is Processed in the Body
|
Phase 1 | |
Completed |
NCT05030857 -
Drug-drug Interaction and Food-effect Study With GLPG4716 and Midazolam in Healthy Subjects
|
Phase 1 | |
Completed |
NCT04967157 -
Cognitive Effects of Citicoline on Attention in Healthy Men and Women
|
N/A | |
Recruiting |
NCT04714294 -
Evaluate the Safety, Tolerability and Pharmacokinetics Characteristics of HPP737 in Healthy Volunteers
|
Phase 1 | |
Recruiting |
NCT04494269 -
A Study to Evaluate Pharmacokinetics and Safety of Tegoprazan in Subjects With Hepatic Impairment and Healthy Controls
|
Phase 1 | |
Completed |
NCT04539756 -
Writing Activities and Emotions
|
N/A | |
Recruiting |
NCT04098510 -
Concentration of MitoQ in Human Skeletal Muscle
|
N/A | |
Completed |
NCT03308110 -
Bioavailability and Food Effect Study of Two Formulations of PF-06650833
|
Phase 1 |